FR2726004B1 - ex vivo tumor cell treatment method for patients with lmc - Google Patents

ex vivo tumor cell treatment method for patients with lmc

Info

Publication number
FR2726004B1
FR2726004B1 FR9412673A FR9412673A FR2726004B1 FR 2726004 B1 FR2726004 B1 FR 2726004B1 FR 9412673 A FR9412673 A FR 9412673A FR 9412673 A FR9412673 A FR 9412673A FR 2726004 B1 FR2726004 B1 FR 2726004B1
Authority
FR
France
Prior art keywords
lmc
patients
treatment method
tumor cell
ex vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9412673A
Other languages
French (fr)
Other versions
FR2726004A1 (en
Inventor
Marta Blumenfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serono Genetics Institute SA
Original Assignee
Serono Genetics Institute SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Genetics Institute SA filed Critical Serono Genetics Institute SA
Priority to FR9412673A priority Critical patent/FR2726004B1/en
Publication of FR2726004A1 publication Critical patent/FR2726004A1/en
Application granted granted Critical
Publication of FR2726004B1 publication Critical patent/FR2726004B1/en
Anticipated expiration legal-status Critical
Application status is Expired - Fee Related legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3511Conjugate intercalating or cleaving agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3513Protein; Peptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
FR9412673A 1994-10-24 1994-10-24 ex vivo tumor cell treatment method for patients with lmc Expired - Fee Related FR2726004B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9412673A FR2726004B1 (en) 1994-10-24 1994-10-24 ex vivo tumor cell treatment method for patients with lmc

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9412673A FR2726004B1 (en) 1994-10-24 1994-10-24 ex vivo tumor cell treatment method for patients with lmc
EP19950936593 EP0804567A1 (en) 1994-10-24 1995-10-23 Method for the ex vivo treatment of tumour cells from patients with cml
PCT/FR1995/001398 WO1996012803A1 (en) 1994-10-24 1995-10-23 Method for the ex vivo treatment of tumour cells from patients with cml

Publications (2)

Publication Number Publication Date
FR2726004A1 FR2726004A1 (en) 1996-04-26
FR2726004B1 true FR2726004B1 (en) 1997-01-10

Family

ID=9468132

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9412673A Expired - Fee Related FR2726004B1 (en) 1994-10-24 1994-10-24 ex vivo tumor cell treatment method for patients with lmc

Country Status (3)

Country Link
EP (1) EP0804567A1 (en)
FR (1) FR2726004B1 (en)
WO (1) WO1996012803A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046672A2 (en) * 1996-06-05 1997-12-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Antisense nucleic acids and hammerhead ribozymes
GB0821457D0 (en) * 2008-11-24 2008-12-31 Trillion Genomics Ltd Oligonucleotides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2103377A1 (en) * 1991-06-18 1992-12-19 Bruno Calabretta Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides

Also Published As

Publication number Publication date
FR2726004A1 (en) 1996-04-26
EP0804567A1 (en) 1997-11-05
WO1996012803A1 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
DE69518154T2 (en) Treatment of diabetes
BR9711245A (en) Treatment derivative containing bio l-c squid live yeast
NO953838D0 (en) Removable medical electrode system
FR2723315B1 (en) Method and composition for stimulating differentiation of preadipocyte cells and therapeutic treatments associated
NO20015546D0 (en) Treatment of refrakt¶re human tumors with epidermal growth factor
DE3855489T2 (en) Treatment of skin wrinkles
DE59508144D1 (en) Gene therapy treatment of vascular disease by a cell-specific, cell cycle-dependent drug
DE69019366D1 (en) Method and composition for treatment of solid tumors.
DE69013771T2 (en) Dental inserts in the treatment of periodontal disease.
NO970215D0 (en) Stimulation agent for hard tissue
EE05025B1 (en) Fumaric acid derivatives for use in the treatment of graft reaction
RU96119344A (en) A method and apparatus for supporting a patient and for providing it with a therapeutic treatment
NO993567D0 (en) Vevsfaktormetoder and compositions for coagulation and tumor treatment
RU99103303A (en) The therapeutic compounds with multiple specificity (embodiments), a method of destroying or reducing the number of unwanted cells in the body, the method of treatment (variants) and the method of vaccination (variants) of the subject, the method fca-receptor modulation in a subject identification method and a method of designing an agent which modulates fca receptors
DE69609868D1 (en) New steroidester for treatment of skin diseases
NO923917L (en) Gene therapy of cell proliferative diseases
DE69507912D1 (en) Endodontic treatment system
NO20013071L (en) Methods and compositions for treating cell proliferative diseases
BR9507506A (en) A method for exterminating one process cell composition for cancer treatment is therapeutic kit
FI952721A0 (en) Substance liver bile for the treatment of diseases
NO984431L (en) FremgangsmÕte for treating pain
FI104044B1 (en) The preparation for use in the treatment of teeth
DE69230755D1 (en) Porphycene for photodynamic therapy
DE69505391D1 (en) Implanted device with tumor cells for treating cancer
DE69026081D1 (en) Subcutaneous electrodes for defibrillation

Legal Events

Date Code Title Description
ST Notification of lapse